Adnexus, A Bristol-Myers Squibb R&D Company

About Adnexus, A Bristol-Myers Squibb R&D Company

Adnexus is a Bristol-Myers Squibb R&D Company focused on the discovery and development of a new class of targeted biologics called Adnectins™. Targeted biologics are one of the most exciting and fastest growing areas of therapeutic medicine. These drugs specifically attack a disease target underlying important medical conditions. Until recently, there have been only two classes of targeted biologics: antibodies and soluble receptors. Adnexus is advancing an entirely new class of novel and proprietary targeted biologics. Adnectins are inherently easy to work with and they may offer important advantages over existing antibody and small molecule approaches.
Adnexus was formed in 2002 and remained a venture-financed biotech company until October 2007, when it was acquired by Bristol-Myers Squibb Company (BMS). This acquisition has further accelerated Adnexus' growth and better enabled it to lead the discovery and development of a new class of targeted biologics. With the experience and track record of BMS, Adnexus continues the clinical development of its first Adnectin product, CT-322, and is advancing multiple other Adnectin therapeutics in its pipeline.
Adnexus provides competitive compensation, excellent benefits, an outstanding work environment and career development opportunities. If you join us at Adnexus, you will discover a fun work environment that fosters your pursuit of excellence! Visit the Careers section of the Adnexus website at www.adnexustx.com to get more information about our work environment, benefits and wellness programs.